Kiniksa Pharmaceuticals (KNSA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 16/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.43% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
- Kiniksa Pharmaceuticals International (KNSA) On The ARCALYST Story And Whether Shares Look Fully Valued
- Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
- Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
- Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
- Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
- Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?
- Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Kiniksa Pharmaceuticals.
Full KNSA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.